Nuclear Receptors in atherosclerosis: A superfamily with many 'Goodfellas'

Molecular and Cellular Endocrinology

Volumn 368, Issue 1-2, 2013, Pages 71-84

  Kurakula, Kondababu ^a   Hamers, Anouk A J ^a   De Waard, Vivian ^a   De Vries, Carlie J M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Atherosclerosis; Endothelial cell; Macrophage; Mouse model; Nuclear receptor; Smooth muscle cell

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FARNESOID X RECEPTOR; FARNESOID X RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MINERALOCORTICOID RECEPTOR; NUCLEAR RECEPTOR NR4A3; NUCLEAR RECEPTOR NUR77; NUCLEAR RECEPTOR RELATED FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROGESTERONE RECEPTOR; RETINOIC ACID DERIVATIVE; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOID RELATED ORPHAN RECEPTOR ALPHA; RETINOID RELATED ORPHAN RECEPTOR BETA; RETINOID X RECEPTOR; THYROID RECEPTOR ALPHA; THYROID RECEPTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ATHEROSCLEROSIS; CELL FUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HYPERTENSION; MACROPHAGE; MODULATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; TREATMENT RESPONSE; VASCULAR DISEASE;

ANIMALS; ATHEROSCLEROSIS; HUMANS; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, CALCITRIOL; RECEPTORS, RETINOIC ACID; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 84875270916     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.05.014     Document Type: Review

References (187)

1. Arkenbout E.K., de Waard V., van Bragt M., van Achterberg T.A., Grimbergen J.M., Pichon B., Pannekoek H., de Vries C.J. Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice. Circulation 2002, 106:1530-1535.
2. Barish G.D., Atkins A.R., Downes M., Olson P., Chong L.W., Nelson M., Zou Y., Hwang H., Kang H., Curtiss L., Evans R.M., Lee C.H. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc. Natl. Acad. Sci. USA 2008, 105:4271-4276.
3. Barish G.D., Downes M., Alaynick W.A., Yu R.T., Ocampo C.B., Bookout A.L., Mangelsdorf D.J., Evans R.M. A nuclear receptor atlas: macrophage activation. Mol. Endocrinol. 2005, 19:2466-2477.
4. Bastie J.N., Balitrand N., Guidez F., Guillemot I., Larghero J., Calabresse C., Chomienne C., Delva L. 1 Alpha,25-dihydroxyvitamin D3 transrepresses retinoic acid transcriptional activity via vitamin D receptor in myeloid cells. Mol. Endocrinol. 2004, 18:2685-2699.
5. Billon-Gales A., Fontaine C., Douin-Echinard V., Delpy L., Berges H., Calippe B., Lenfant F., Laurell H., Guery J.C., Gourdy P., Arnal J.F. Endothelial estrogen receptor-alpha plays a crucial role in the atheroprotective action of 17beta-estradiol in low-density lipoprotein receptor-deficient mice. Circulation 2009, 120:2567-2576.
6. Billon-Gales A., Fontaine C., Filipe C., Douin-Echinard V., Fouque M.J., Flouriot G., Gourdy P., Lenfant F., Laurell H., Krust A., Chambon P., Arnal J.F. The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc. Natl. Acad. Sci. USA 2009, 106:2053-2058.
7. Billon-Gales A., Krust A., Fontaine C., Abot A., Flouriot G., Toutain C., Berges H., Gadeau A.P., Lenfant F., Gourdy P., Chambon P., Arnal J.F. Activation function 2 (AF2) of estrogen receptor-alpha is required for the atheroprotective action of estradiol but not to accelerate endothelial healing. Proc. Natl. Acad. Sci. USA 2011, 108:13311-13316.
8. Bishop-Bailey D., Walsh D.T., Warner T.D. Expression and activation of the farnesoid X receptor in the vasculature. Proc. Natl. Acad. Sci. USA 2004, 101:3668-3673.
9. Blaschke F., Leppanen O., Takata Y., Caglayan E., Liu J., Fishbein M.C., Kappert K., Nakayama K.I., Collins A.R., Fleck E., Hsueh W.A., Law R.E., Bruemmer D. Liver X receptor agonists suppress vascular smooth muscle cell proliferation and inhibit neointima formation in balloon-injured rat carotid arteries. Circ. Res. 2004, 95:e110-e123.
10. Bonta P.I., Pols T.W., van Tiel C.M., Vos M., Arkenbout E.K., Rohlena J., Koch K.T., de Maat M.P., Tanck M.W., de Winter R.J., Pannekoek H., Biessen E.A., Bot I., de Vries C.J. Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation. Circulation 2010, 121:2023-2032.
11. Bonta P.I., van Tiel C.M., Vos M., Pols T.W., van Thienen J.V., Ferreira V., Arkenbout E.K., Seppen J., Spek C.A., van der Poll T., Pannekoek H., de Vries C.J. Nuclear receptors Nur77, Nurr1 and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses. Arterioscler. Thromb., Vasc. Biol. 2006, 26:2288-2294.
12. Bouhlel M.A., Derudas B., Rigamonti E., Dievart R., Brozek J., Haulon S., Zawadzki C., Jude B., Torpier G., Marx N., Staels B., Chinetti-Gbaguidi G. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007, 6:137-143.
13. Bour G., Lalevee S., Rochette-Egly C. Protein kinases and the proteasome join in the combinatorial control of transcription by nuclear retinoic acid receptors. Trends Cell Biol. 2007, 17:302-309.
14. Bourghardt J., Wilhelmson A.S., Alexanderson C., De G.K., Verhoeven G., Krettek A., Ohlsson C., Tivesten A. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 2010, 151:5428-5437.
15. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., Lusis A.J., Collins A., Hseuh W.A., Collins J.L., Tangirala R.K., Tontonoz P. Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE. J. Clin. Invest. 2007, 117:2337-2346.
16. Brouchet L., Krust A., Dupont S., Chambon P., Bayard F., Arnal J.F. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001, 103:423-428.
17. Bruemmer D., Law R.E. Liver x receptors: potential novel targets in cardiovascular diseases. Curr. Drug Targets: Cardiovasc. & Haematol. Disord. 2005, 5:533-540.
18. Carmody B.J., Arora S., Wakefield M.C., Weber M., Fox C.J., Sidawy A.N. Progesterone inhibits human infragenicular arterial smooth muscle cell proliferation induced by high glucose and insulin concentrations. J. Vasc. Surg. 2002, 36:833-838.
19. Carrelli A.L., Walker M.D., Lowe H., McMahon D.J., Rundek T., Sacco R.L., Silverberg S.J. Vitamin D deficiency is associated with subclinical carotid atherosclerosis: the Northern Manhattan study. Stroke 2011, 42:2240-2245.
20. Chandrasekar B., Tanguay J.F. Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model. J. Am. Coll. Cardiol. 2000, 36:1972-1978.
21. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 2001, 7:161-171.
22. Chen Z.P., Iyer J., Bourguet W., Held P., Mioskowski C., Lebeau L., Noy N., Chambon P., Gronemeyer H. Ligand- and DNA-induced dissociation of RXR tetramers. J. Mol. Biol. 1998, 275:55-65.
23. Choi Y.H., Park M.J., Kim K.W., Lee H.C., Choi Y.H., Cheong J. The orphan nuclear receptor SHP is involved in monocytic differentiation and its expression is increased by c-Jun. J. Leukoc. Biol. 2004, 76:1082-1088.
24. Clipsham R., McCabe E.R. DAX1 and its network partners: exploring complexity in development. Mol. Genet. Metab. 2003, 80:81-120.
25. Dagre A.G., Lekakis J.P., Protogerou A.D., Douridas G.N., Papaioannou T.G., Tryfonopoulos D.J., Papamichael C.M., Alevizaki M. Abnormal endothelial function in female patients with hypothyroidism and borderline thyroid function. Int. J. Cardiol. 2007, 114:332-338.
26. Darblade B., Pendaries C., Krust A., Dupont S., Fouque M.J., Rami J., Chambon P., Bayard F., Arnal J.F. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circ. Res. 2002, 90:413-419.
27. de Lera A.R., Bourguet W., Altucci L., Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 2007, 6:811-820.
28. de Vries C.J., van Achterberg T.A., Horrevoets A.J., ten Cate J.W., Pannekoek H. Differential display identification of 40 genes with altered expression in activated human smooth muscle cells. Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes. J. Biol. Chem. 2000, 275:23939-23947.
29. de Haan W., de Vries-van der Weij J., Mol I.M., Hoekstra M., Romijn J.A., Jukema J.W., Havekes L.M., Princen H.M., Rensen P.C. PXR agonism decreases plasma HDL levels in ApoE3-Leiden. CETP mice. Biochim. Biophys. Acta 2009, 1791:191-197.
30. de Waard V., Arkenbout E.K., Vos M., Mocking A.I., Niessen H.W., Stooker W., de Mol B.A., Quax P.H., Bakker E.N., VanBavel E., Pannekoek H., de Vries C.J. TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells. Am. J. Pathol. 2006, 168:2027-2035.
31. Delerive P., De B.K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 1999, 274:32048-32054.
32. Delerive P., Monte D., Dubois G., Trottein F., Fruchart-Najib J., Mariani J., Fruchart J.C., Staels B. The orphan nuclear receptor ROR alpha is a negative regulator of the inflammatory response. EMBO Rep. 2001, 2:42-48.
33. Deuchar G.A., McLean D., Hadoke P.W., Brownstein D.G., Webb D.J., Mullins J.J., Chapman K., Seckl J.R., Kotelevtsev Y.V. 11beta-hydroxysteroid dehydrogenase type 2 deficiency accelerates atherogenesis and causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 2011, 152:236-246.
34. Duong V., Rochette-Egly C. The molecular physiology of nuclear retinoic acid receptors. From health to disease. Biochim. Biophys. Acta 2011, 1812:1023-1031.
35. Ehrlund A., Treuter E. Ligand-independent actions of the orphan receptors/corepressors DAX-1 and SHP in metabolism, reproduction and disease. J. Steroid Biochem. Mol. Biol. 2011, 130:169-179.
36. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30 and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649-1660.
37. Flaig R., Greschik H., Peluso-Iltis C., Moras D. Structural basis for the cell-specific activities of the NGFI-B and the Nurr1 ligand-binding domain. J. Biol. Chem. 2005, 280:19250-19258.
38. Fujiu K., Manabe I., Ishihara A., Oishi Y., Iwata H., Nishimura G., Shindo T., Maemura K., Kagechika H., Shudo K., Nagai R. Synthetic retinoid Am80 suppresses smooth muscle phenotypic modulation and in-stent neointima formation by inhibiting KLF5. Circ. Res. 2005, 97:1132-1141.
39. Gaetano C., Catalano A., Illi B., Felici A., Minucci S., Palumbo R., Facchiano F., Mangoni A., Mancarella S., Muhlhauser J., Capogrossi M.C. Retinoids induce fibroblast growth factor-2 production in endothelial cells via retinoic acid receptor alpha activation and stimulate angiogenesis in vitro and in vivo. Circ. Res. 2001, 88:E38-E47.
40. Geraldes P., Sirois M.G., Bernatchez P.N., Tanguay J.F. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 2002, 22:1585-1590.
41. Ghisletti S., Huang W., Jepsen K., Benner C., Hardiman G., Rosenfeld M.G., Glass C.K. Cooperative NCoR/SMRT interactions establish a corepressor-based strategy for integration of inflammatory and anti-inflammatory signaling pathways. Genes Dev. 2009, 23:681-693.
42. Gizard F., Amant C., Barbier O., Bellosta S., Robillard R., Percevault F., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J.C., Torpier G., Staels B. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J. Clin. Invest. 2005, 115:3228-3238.
43. Gizard F., Zhao Y., Findeisen H.M., Qing H., Cohn D., Heywood E.B., Jones K.L., Nomiyama T., Bruemmer D. Transcriptional regulation of S phase kinase-associated protein 2 by NR4A orphan nuclear receptor NOR1 in vascular smooth muscle cells. J. Biol. Chem. 2011, 286:35485-35493.
44. Goodwin J.E., Zhang J., Gonzalez D., Albinsson S., Geller D.S. Knockout of the vascular endothelial glucocorticoid receptor abrogates dexamethasone-induced hypertension. J. Hypertens. 2011, 29:1347-1356.
45. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277:34182-34190.
46. Gruber F., Hufnagl P., Hofer-Warbinek R., Schmid J.A., Breuss J.M., Huber-Beckmann R., Lucerna M., Papac N., Harant H., Lindley I., de Martin R., Binder B.R. Direct binding of Nur77/NAK-1 to the plasminogen activator inhibitor 1 (PAI-1) promoter regulates TNF alpha -induced PAI-1 expression. Blood 2003, 101:3042-3048.
47. Gudas L.J., Wagner J.A. Retinoids regulate stem cell differentiation. J. Cell Physiol. 2011, 226:322-330.
48. Guo G.L., Santamarina-Fojo S., Akiyama T.E., Amar M.J., Paigen B.J., Brewer B., Gonzalez F.J. Effects of FXR in foam-cell formation and atherosclerosis development. Biochim. Biophys. Acta 2006, 1761:1401-1409.
49. Hageman J., Herrema H., Groen A.K., Kuipers F. A role of the bile salt receptor FXR in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1519-1528.
50. Hamers A.A., Vos M., Rassam F., Marincovic G., Kurakula K., van Gorp P.J., de Winther M.P., Gijbels M.J., de Waard, V, de Vries C.J. Bone marrow-specific deficiency of nuclear receptor nur77 enhances atherosclerosis. Circ. Res. 2012, 110:428-438.
51. Hanna R.N., Shaked I., Hubbeling H.G., Punt J.A., Wu R., Herrley E., Zaugg C., Pei H., Geissmann F., Ley K., Hedrick C.C. NR4A1 (Nur77) deletion polarizes macrophages toward an inflammatory phenotype and increases atherosclerosis. Circ. Res. 2012, 110:416-427.
52. Hanniman E.A., Lambert G., McCarthy T.C., Sinal C.J. Loss of functional farnesoid X receptor increases atherosclerotic lesions in apolipoprotein E-deficient mice. J. Lipid Res. 2005, 46:2595-2604.
53. Hartman H.B., Gardell S.J., Petucci C.J., Wang S., Krueger J.A., Evans M.J. Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- mice. J. Lipid Res. 2009, 50:1090-1100.
54. Hodgin J.B., Krege J.H., Reddick R.L., Korach K.S., Smithies O., Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J. Clin. Invest. 2001, 107:333-340.
55. Hoekstra M., Lammers B., Out R., Li Z., Van E.M., Van Berkel T.J. Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol. Pharm. 2009, 6:182-189.
56. Horard B., Vanacker J.M. Estrogen receptor-related receptors: orphan receptors desperately seeking a ligand. J. Mol. Endocrinol. 2003, 31:349-357.
57. Hsu S.P., Chen T.H., Chou Y.P., Chen L.C., Kuo C.T., Lee T.S., Lin J.J., Chang N.C., Lee W.S. Extra-nuclear activation of progesterone receptor in regulating arterial smooth muscle cell migration. Atherosclerosis 2011, 217:83-89.
58. Huang W., Ghisletti S., Saijo K., Gandhi M., Aouadi M., Tesz G.J., Zhang D.X., Yao J., Czech M.P., Goode B.L., Rosenfeld M.G., Glass C.K. Coronin 2A mediates actin-dependent de-repression of inflammatory response genes. Nature 2011, 470:414-418.
59. Ikeda Y., Aihara K., Yoshida S., Sato T., Yagi S., Iwase T., Sumitomo Y., Ise T., Ishikawa K., Azuma H., Akaike M., Kato S., Matsumoto T. Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrinology 2009, 150:2857-2864.
60. Im S.S., Osborne T.F. Liver X receptors in atherosclerosis and inflammation. Circ. Res. 2011, 108:996-1001.
61. Imayama I., Ichiki T., Patton D., Inanaga K., Miyazaki R., Ohtsubo H., Tian Q., Yano K., Sunagawa K. Liver X receptor activator downregulates angiotensin II type 1 receptor expression through dephosphorylation of Sp1. Hypertension 2008, 51:1631-1636.
62. Ishibashi S., Goldstein J.L., Brown M.S., Herz J., Burns D.K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 1994, 93:1885-1893.
63. Iwakura A., Luedemann C., Shastry S., Hanley A., Kearney M., Aikawa R., Isner J.M., Asahara T., Losordo D.W. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 2003, 108:3115-3121.
64. Jetten A.M., Kurebayashi S., Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog. Nucleic Acid Res. Mol. Biol. 2001, 69:205-247.
65. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 2003, 9:213-219.
66. Karas R.H., van Eickels M., Lydon J.P., Roddy S., Kwoun M., Aronovitz M., Baur W.E., Conneely O., O'Malley B.W., Mendelsohn M.E. A complex role for the progesterone receptor in the response to vascular injury. J. Clin. Invest. 2001, 108:611-618.
67. Kersten S., Kelleher D., Chambon P., Gronemeyer H., Noy N. Retinoid X receptor alpha forms tetramers in solution. Proc. Natl. Acad. Sci. USA 1995, 92:8645-8649.
68. Khogali A.M., Chazan B.I., Metcalf V.J., Ramsay J.H. Hyperlipidaemia as a complication of rifampicin treatment. Tubercle 1974, 55:231-233.
69. Kim H.J., Kim M.Y., Jin H., Kim H.J., Kang S.S., Kim H.J., Lee J.H., Chang K.C., Hwang J.Y., Yabe-Nishimura C., Kim J.H., Seo H.G. Peroxisome proliferator-activated receptor delta regulates extracellular matrix and apoptosis of vascular smooth muscle cells through the activation of transforming growth factor-{beta}1/Smad3. Circ. Res. 2009, 105:16-24.
70. Kim J., Kim J.Y., Song K.S., Lee Y.H., Seo J.S., Jelinek J., Goldschmidt-Clermont P.J., Issa J.P. Epigenetic changes in estrogen receptor beta gene in atherosclerotic cardiovascular tissues and in vitro vascular senescence. Biochim. Biophys. Acta 2007, 1772:72-80.
71. Klein I., Danzi S. Thyroid disease and the heart. Circulation 2007, 116:1725-1735.
72. Laitinen S., Staels B. Potential roles of ROR-alpha in cardiovascular endocrinology. Nucl. Recept. Signal. 2003, 1:e011.
73. Lalloyer F., Pedersen T.A., Gross B., Lestavel S., Yous S., Vallez E., Gustafsson J.A., Mandrup S., Fiévet C., Staels B., Tailleux A. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1488-1495.
74. Lavie C.J., Lee J.H., Milani R.V. Vitamin D and cardiovascular disease will it live up to its hype?. J. Am. Coll. Cardiol. 2011, 58:1547-1556.
75. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
76. Lee C.H., Chawla A., Urbiztondo N., Liao D., Boisvert W.A., Evans R.M., Curtiss L.K. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003, 302:453-457.
77. Lee K.M., Seo H.Y., Kim M.K., Min A.K., Ryu S.Y., Kim Y.N., Park Y.J., Choi H.S., Lee K.U., Park W.J., Park K.G., Lee I.K. Orphan nuclear receptor small heterodimer partner inhibits angiotensin II- stimulated PAI-1 expression in vascular smooth muscle cells. Exp. Mol. Med. 2010, 42:21-29.
78. Leuschner F., Panizzi P., Chico-Calero I., Lee W.W., Ueno T., Cortez-Retamozo V., Waterman P., Gorbatov R., Marinelli B., Iwamoto Y., Chudnovskiy A., Figueiredo J.L., Sosnovik D.E., Pittet M.J., Swirski F.K., Weissleder R., Nahrendorf M. Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ. Res. 2010, 107:1364-1373.
79. Levin N., Bischoff E.D., Daige C.L., Thomas D., Vu C.T., Heyman R.A., Tangirala R.K., Schulman I.G. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 2005, 25:135-142.
80. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta and gamma. J. Clin. Invest. 2004, 114:1564-1576.
81. Li G., Biju K.C., Xu X., Zhou Q., Chen C., Valente A.J., He W., Reddick R.L., Freeman G.L., Ahuja S.S., Clark R.A., Li S. Macrophage LXRalpha gene therapy ameliorates atherosclerosis as well as hypertriglyceridemia in LDLR(-/-) mice. Gene Ther. 2011, 18:835-841.
82. Li J., Wilson A., Kuruba R., Zhang Q., Gao X., He F., Zhang L.M., Pitt B.R., Xie W., Li S. FXR-mediated regulation of eNOS expression in vascular endothelial cells. Cardiovasc. Res. 2008, 77:169-177.
83. Li Y.C., Kong J., Wei M., Chen Z.F., Liu S.Q., Cao L.P. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002, 110:229-238.
84. Li Y.T., Swales K.E., Thomas G.J., Warner T.D., Bishop-Bailey D. Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2606-2611.
85. Liao H., Langmann T., Schmitz G., Zhu Y. Native LDL upregulation of ATP-binding cassette transporter-1 in human vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2002, 22:127-132.
86. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
87. Lin F.J., Qin J., Tang K., Tsai S.Y., Tsai M.J. Coup d'Etat: an orphan takes control. Endocrinol. Rev. 2011, 32:404-421.
88. Liu D., Jia H., Holmes D.I., Stannard A., Zachary I. Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1 and Nor1. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2002-2007.
89. Liu P.Y., Christian R.C., Ruan M., Miller V.M., Fitzpatrick L.A. Correlating androgen and estrogen steroid receptor expression with coronary calcification and atherosclerosis in men without known coronary artery disease. J. Clin. Endocrinol. Metab. 2005, 90:1041-1046.
90. Lusis A.J., Fogelman A.M., Fonarow G.C. Genetic basis of atherosclerosis: part I: new genes and pathways. Circulation 2004, 110:1868-1873.
91. Maitra U., Parks J.S., Li L. An innate immunity signaling process suppresses macrophage ABCA1 expression through IRAK-1-mediated downregulation of retinoic acid receptor alpha and NFATc2. Mol. Cell Biol. 2009, 29:5989-5997.
92. Mamontova A., Seguret-Mace S., Esposito B., Chaniale C., Bouly M., Delhaye-Bouchaud N., Luc G., Staels B., Duverger N., Mariani J., Tedgui A. Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. Circulation 1998, 98:2738-2743.
93. Martinez-Gonzalez J., Rius J., Castello A., Cases-Langhoff C., Badimon L. Neuron-derived orphan receptor-1 (NOR-1) modulates vascular smooth muscle cell proliferation. Circ. Res. 2003, 92:96-103.
94. Martorell L., Martinez-Gonzalez J., Crespo J., Calvayrac O., Badimon L. Neuron-derived orphan receptor-1 (NOR-1) is induced by thrombin and mediates vascular endothelial cell growth. J. Thromb. Haemost. 2007, 5:1766-1773.
95. Marx N., Sukhova G.K., Collins T., Libby P., Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
96. McCurley A., Jaffe I.Z. Mineralocorticoid receptors in vascular function and disease. Mol. Cell Endocrinol. 2012, 350:256-265.
97. Mencarelli A., Renga B., Distrutti E., Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am. J. Physiol Heart Circ. Physiol. 2009, 296:H272-H281.
98. Mendelsohn C., Lohnes D., Decimo D., Lufkin T., LeMeur M., Chambon P., Mark M. Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development 1994, 120:2749-2771.
99. Menzies F.M., Henriquez F.L., Alexander J., Roberts C.W. Selective inhibition and augmentation of alternative macrophage activation by progesterone. Immunology. 2011, 134:281-291.
100. Meredith D., Panchatcharam M., Miriyala S., Tsai Y.S., Morris A.J., Maeda N., Stouffer G.A., Smyth S.S. Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration and vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 2009, 29:465-471.
101. Myers S.A., Wang S.C., Muscat G.E. The chicken ovalbumin upstream promoter-transcription factors modulate genes and pathways involved in skeletal muscle cell metabolism. J. Biol. Chem. 2006, 281:24149-24160.
102. Nagy L., Schwabe J.W. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 2004, 29:317-324.
103. Nakamura Y., Suzuki T., Igarashi K., Kanno J., Furukawa T., Tazawa C., Fujishima F., Miura I., Ando T., Moriyama N., Moriya T., Saito H., Yamada S., Sasano H. PTOV1: a novel testosterone-induced atherogenic gene in human aorta. J. Pathol. 2006, 209:522-531.
104. Nettleship J.E., Jones T.H., Channer K.S., Jones R.D. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 2007, 116:2427-2434.
105. Nheu L., Nazareth L., Xu G.Y., Xiao F.Y., Luo R.Z., Komesaroff P., Ling S. Physiological effects of androgens on human vascular endothelial and smooth muscle cells in culture. Steroids 2011, 76:1590-1596.
106. Nickenig G., Strehlow K., Wassmann S., Baumer A.T., Albory K., Sauer H., Bohm M. Differential effects of estrogen and progesterone on AT(1) receptor gene expression in vascular smooth muscle cells. Circulation 2000, 102:1828-1833.
107. Nomiyama T., Nakamachi T., Gizard F., Heywood E.B., Jones K.L., Ohkura N., Kawamori R., Conneely O.M., Bruemmer D. The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J. Biol. Chem. 2006, 281:33467-33476.
108. Nomiyama T., Zhao Y., Gizard F., Findeisen H.M., Heywood E.B., Jones K.L., Conneely O.M., Bruemmer D. Deficiency of the NR4A neuron-derived orphan receptor-1 attenuates neointima formation after vascular injury. Circulation 2009, 119:577-586.
109. Norata G.D., Cattaneo P., Poletti A., Catapano A.L. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits tumor necrosis factor alpha and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. Atherosclerosis 2010, 212:100-106.
110. Nuclear Receptors Nomenclature Committee A unified nomenclature system for the nuclear receptor superfamily. Cell 1999, 97:161-163.
111. Oh J., Weng S., Felton S.K., Bhandare S., Riek A., Butler B., Proctor B.M., Petty M., Chen Z., Schechtman K.B., Bernal-Mizrachi L., Bernal-Mizrachi C. 1,25(OH)2 vitamin d inhibits foam cell formation and suppresses macrophage cholesterol uptake in patients with type 2 diabetes mellitus. Circulation 2009, 120:687-698.
112. Okayasu T., Tomizawa A., Suzuki K., Manaka K., Hattori Y. PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation. Life Sci. 2008, 82:884-891.
113. Pei L., Castrillo A., Chen M., Hoffmann A., Tontonoz P. Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J. Biol. Chem. 2005, 280:29256-29262.
114. Pereira F.A., Qiu Y., Zhou G., Tsai M.J., Tsai S.Y. The orphan nuclear receptor COUP-TFII is required for angiogenesis and heart development. Genes Dev. 1999, 13:1037-1049.
115. Perez E., Bourguet W., Gronemeyer H., de Lera A.R. Modulation of RXR function through ligand design. Biochim. Biophys. Acta 2012, 1821:57-69.
116. Pires N.M., Pols T.W., de Vries M.R., van Tiel C.M., Bonta P.I., Vos M., Arkenbout E.K., Pannekoek H., Jukema J.W., Quax P.H., de Vries C.J. Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 2007, 115:493-500.
117. Plump A.S., Smith J.D., Hayek T., Aalto-Setälä K., Walsh A., Verstuyft J.G., Rubin E.M., Breslow J.L. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E deficient mice created by homologous recombination in ES cells. Cell 1992, 71:343-353.
118. Plutzky J. The PPAR-RXR transcriptional complex in the vasculature: energy in the balance. Circ. Res. 2011, 108:1002-1016.
119. Pols T.W., Bonta P.I., de Vries C.J. NR4A nuclear orphan receptors: protective in vascular disease?. Curr Opin Lipidol. 2007, 18:515-520.
120. Pols T.W., Nomura M., Harach T., Lo S.G., Oosterveer M.H., Thomas C., Rizzo G., Gioiello A., Adorini L., Pellicciari R., Auwerx J., Schoonjans K. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab. 2011, 14:747-757.
121. Poon M., Gertz S.D., Fallon J.T., Wiegman P., Berman J.W., Sarembock I.J., Taubman M.B. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis 2001, 155:371-380.
122. Post W.S., Goldschmidt-Clermont P.J., Wilhide C.C., Heldman A.W., Sussman M.S., Ouyang P., Milliken E.E., Issa J.P. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc. Res. 1999, 43:985-991.
123. Preusch M.R., Rattazzi M., Albrecht C., Merle U., Tuckermann J., Schutz G., Blessing E., Zoppellaro G., Pauletto P., Krempien R., Rosenfeld M.E., Katus H.A., Bea F. Critical role of macrophages in glucocorticoid driven vascular calcification in a mouse-model of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2158-2164.
124. Qiu Y., Yanase T., Hu H., Tanaka T., Nishi Y., Liu M., Sueishi K., Sawamura T., Nawata H. Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology 2010, 151:3307-3316.
125. Razvi S., Ingoe L., Keeka G., Oates C., McMillan C., Weaver J.U. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: randomized, crossover trial. J. Clin. Endocrinol. Metab. 2007, 92:1715-1723.
126. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
127. Rhee E.J., Nallamshetty S., Plutzky J. Retinoid metabolism and its effects on the vasculature. Biochim. Biophys. Acta 2012, 1821:230-240.
128. Ribas V., Drew B.G., Le J.A., Soleymani T., Daraei P., Sitz D., Mohammad L., Henstridge D.C., Febbraio M.A., Hewitt S.C., Korach K.S., Bensinger S.J., Hevener A.L. Myeloid-specific estrogen receptor alpha deficiency impairs metabolic homeostasis and accelerates atherosclerotic lesion development. Proc. Natl. Acad. Sci. USA 2011, 108:16457-16462.
129. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
130. Ringseis R., Gahler S., Eder K. Conjugated linoleic acid isomers inhibit platelet-derived growth factor-induced NF-kappaB transactivation and collagen formation in human vascular smooth muscle cells. Eur. J. Nutr. 2008, 47:59-67.
131. Rius J., Martinez-Gonzalez J., Crespo J., Badimon L. NOR-1 is involved in VEGF-induced endothelial cell growth. Atherosclerosis 2006, 184:276-282.
132. Rochette-Egly C., Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs). Nucl. Recept. Signal. 2009, 7:e005.
133. Rosenfeld M.E., Kauser K., Martin-McNulty B., Polinsky P., Schwartz S.M., Rubanyi G.M. Estrogen inhibits the initiation of fatty streaks throughout the vasculature but does not inhibit intra-plaque hemorrhage and the progression of established lesions in apolipoprotein E deficient mice. Atherosclerosis 2002, 164:251-259.
134. Rossouw J.E., Prentice R.L., Manson J.E., Wu L., Barad D., Barnabei V.M., Ko M., LaCroix A.Z., Margolis K.L., Stefanick M.L. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007, 297:1465-1477.
135. Roth A., Looser R., Kaufmann M., Blattler S.M., Rencurel F., Huang W., Moore D.D., Meyer U.A. Regulatory cross-talk between drug metabolism and lipid homeostasis: constitutive androstane receptor and pregnane X receptor increase Insig-1 expression. Mol. Pharmacol. 2008, 73:1282-1289.
136. Routley C.E., Ashcroft G.S. Effect of estrogen and progesterone on macrophage activation during wound healing. Wound. Repair Regen. 2009, 17:42-50.
137. Ruan Q., Kameswaran V., Zhang Y., Zheng S., Sun J., Wang J., DeVirgiliis J., Liou H.C., Beg A.A., Chen Y.H. The Th17 immune response is controlled by the Rel-RORgamma-RORgamma T transcriptional axis. J. Exp. Med. 2011, 208:2321-2333.
138. Rupprecht R., Reul J.M., van Steensel B., Spengler D., Soder M., Berning B., Holsboer F., Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur. J. Pharmacol. 1993, 247:145-154.
139. Sberna A.L., Assem M., Gautier T., Grober J., Guiu B., Jeannin A., Pais de Barros J.P., Athias A., Lagrost L., Masson D. Constitutive androstane receptor activation stimulates faecal bile acid excretion and reverse cholesterol transport in mice. J. Hepatol. 2011, 55:154-161.
140. Sberna A.L., Assem M., Xiao R., Ayers S., Gautier T., Guiu B., Deckert V., Chevriaux A., Grober J., Le G.N., Pais de Barros J.P., Moore D.D., Lagrost L., Masson D. Constitutive androstane receptor activation decreases plasma apolipoprotein B-containing lipoproteins and atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2011, 31:2232-2239.
141. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
142. Seol W., Choi H.S., Moore D.D. An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. Science 1996, 272:1336-1339.
143. Shafran S.D., Mashinter L.D., Roberts S.E. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med. 2005, 6:421-425.
144. Shao Q., Shen L.H., Hu L.H., Pu J., Qi M.Y., Li W.Q., Tian F.J., Jing Q., He B. Nuclear receptor Nur77 suppresses inflammatory response dependent on COX-2 in macrophages induced by oxLDL. J. Mol. Cell Cardiol. 2010, 49:304-311.
145. Shindo T., Manabe I., Fukushima Y., Tobe K., Aizawa K., Miyamoto S., Kawai-Kowase K., Moriyama N., Imai Y., Kawakami H., Nishimatsu H., Ishikawa T., Suzuki T., Morita H., Maemura K., Sata M., Hirata Y., Komukai M., Kagechika H., Kadowaki T., Kurabayashi M., Nagai R. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 2002, 8:856-863.
146. Sonoda J., Laganiere J., Mehl I.R., Barish G.D., Chong L.W., Li X., Scheffler I.E., Mock D.C., Bataille A.R., Robert F., Lee C.H., Giguere V., Evans R.M. Nuclear receptor ERR alpha and coactivator PGC-1 beta are effectors of IFN-gamma-induced host defense. Genes Dev. 2007, 21:1909-1920.
147. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
148. Sui Y., Xu J., Rios-Pilier J., Zhou C. Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J. Lipid Res. 2011, 52:1652-1659.
149. Sumi D., Ignarro L.J. Estrogen-related receptor alpha 1 up-regulates endothelial nitric oxide synthase expression. Proc. Natl. Acad. Sci. USA 2003, 100:14451-14456.
150. Surjit M., Ganti K.P., Mukherji A., Ye T., Hua G., Metzger D., Li M., Chambon P. Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 2011, 145:224-241.
151. Swales K.E., Moore R., Truss N.J., Tucker A., Warner T.D., Negishi M., Bishop-Bailey D. Pregnane X receptor regulates drug metabolism and transport in the vasculature and protects from oxidative stress. Cardiovasc. Res. 2012, 93:674-681.
152. Takeda M., Yamashita T., Sasaki N., Nakajima K., Kita T., Shinohara M., Ishida T., Hirata K. Oral administration of an active form of vitamin D3 (calcitriol) decreases atherosclerosis in mice by inducing regulatory T cells and immature dendritic cells with tolerogenic functions. Arterioscler. Thromb. Vasc. Biol. 2010, 30:2495-2503.
153. Takeda N., Manabe I., Shindo T., Iwata H., Iimuro S., Kagechika H., Shudo K., Nagai R. Synthetic retinoid Am80 reduces scavenger receptor expression and atherosclerosis in mice by inhibiting IL-6. Arterioscler. Thromb. Vasc. Biol. 2006, 26:1177-1183.
154. Tancevski I., Rudling M., Eller P. Thyromimetics: a journey from bench to bed-side. Pharmacol. Ther. 2011, 131:33-39.
155. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J., Wang X., Lusis A.J., Tontonoz P., Schulman I.G. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA 2002, 99:11896-11901.
156. Teupser D., Kretzschmar D., Tennert C., Burkhardt R., Wilfert W., Fengler D., Naumann R., Sippel A.E., Thiery J. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 2008, 28:2009-2015.
157. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
158. Toutain C.E., Filipe C., Billon A., Fontaine C., Brouchet L., Guery J.C., Gourdy P., Arnal J.F., Lenfant F. Estrogen receptor alpha expression in both endothelium and hematopoietic cells is required for the accelerative effect of estradiol on reendothelialization. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1543-1550.
159. Umetani M., Domoto H., Gormley A.K., Yuhanna I.S., Cummins C.L., Javitt N.B., Korach K.S., Shaul P.W., Mangelsdorf D.J. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 2007, 13:1185-1192.
160. Uruno A., Sugawara A., Kanatsuka H., Kagechika H., Saito A., Sato K., Kudo M., Takeuchi K., Ito S. Upregulation of nitric oxide production in vascular endothelial cells by all-trans retinoic acid through the phosphoinositide 3-kinase/Akt pathway. Circulation 2005, 112:727-736.
161. Usher M.G., Duan S.Z., Ivaschenko C.Y., Frieler R.A., Berger S., Schutz G., Lumeng C.N., Mortensen R.M. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J. Clin. Invest. 2010, 120:3350-3364.
162. van der Pouw Kraan T.C., Schirmer S.H., Fledderus J.O., Moerland P.D., Baggen J.M., Leyen T.A., van der Laan A.M., Piek J.J., van Royen N., Horrevoets A.J. Expression of a retinoic acid signature in circulating CD34 cells from coronary artery disease patients. BMC Genomics 2010, 11:388.
163. van Tiel C.M., de Vries C.J. NR4All in the vessel wall. J. Steroid Biochem. Mol. Biol. 2012, 130:186-193.
164. Verschuren L., de Vries-van der Weij J., Zadelaar S., Kleemann R., Kooistra T. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in apoE*3Leiden mice: time course and mechanisms. J. Lipid Res. 2009, 50:301-311.
165. Villa A.E., Guzman L.A., Chen W., Golomb G., Levy R.J., Topol E.J. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J. Clin. Invest. 1994, 93:1243-1249.
166. Villablanca A., Lubahn D., Shelby L., Lloyd K., Barthold S. Susceptibility to early atherosclerosis in male mice is mediated by estrogen receptor alpha. Arterioscler. Thromb. Vasc. Biol. 2004, 24:1055-1061.
167. Wang Z., Benoit G., Liu J., Prasad S., Aarnisalo P., Liu X., Xu H., Walker N.P., Perlmann T. Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature 2003, 423:555-560.
168. Wassmann K., Wassmann S., Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ. Res. 2005, 97:1046-1054.
169. Weber C., Zernecke A., Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol. 2008, 8:802-815.
170. Wu-Wong J.R., Nakane M., Ma J., Ruan X., Kroeger P.E. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 2006, 186:20-28.
171. Ying A.K., Hassanain H.H., Roos C.M., Smiraglia D.J., Issa J.J., Michler R.E., Caligiuri M., Plass C., Goldschmidt-Clermont P.J. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc. Res. 2000, 46:172-179.
172. Yokota J., Kawana M., Hidai C., Aoka Y., Ichikawa K., Iguchi N., Okada M., Kasanuki H. Retinoic acid suppresses endothelin-1 gene expression at the transcription level in endothelial cells. Atherosclerosis 2001, 159:491-496.
173. Yuk J.M., Shin D.M., Lee H.M., Kim J.J., Kim S.W., Jin H.S., Yang C.S., Park K.A., Chanda D., Kim D.K., Huang S.M., Lee S.K., Lee C.H., Kim J.M., Song C.H., Lee S.Y., Hur G.M., Moore D.D., Choi H.S., Jo E.K. The orphan nuclear receptor SHP acts as a negative regulator in inflammatory signaling triggered by Toll-like receptors. Nat. Immunol. 2011, 12:742-751.
174. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
175. Zelcer N., Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 2006, 116:607-614.
176. Zeng H., Qin L., Zhao D., Tan X., Manseau E.J., Van H.M., Senger D.R., Brown L.F., Nagy J.A., Dvorak H.F. Orphan nuclear receptor TR3/Nur77 regulates VEGF-A-induced angiogenesis through its transcriptional activity. J. Exp. Med. 2006, 203:719-729.
177. Zhang S.H., Reddick R.L., Piedrahita J.A., Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992, 258:468-471.
178. Zhang Y., Wang X., Vales C., Lee F.Y., Lee H., Lusis A.J., Edwards P.A. FXR deficiency causes reduced atherosclerosis in Ldlr-/- mice. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2316-2321.
179. Zhang Q., He F., Kuruba R., Gao X., Wilson A., Li J., Billiar T.R., Pitt B.R., Xie W., Li S. FXR-mediated regulation of angiotensin type 2 receptor expression in vascular smooth muscle cells. Cardiovasc. Res. 2008, 77:560-569.
180. Zhang X.H., Zheng B., Han M., Miao S.B., Wen J.K. Synthetic retinoid Am80 inhibits interaction of KLF5 with RAR alpha through inducing KLF5 dephosphorylation mediated by the PI3K/Akt signaling in vascular smooth muscle cells. FEBS Lett. 2009, 583:1231-1236.
181. Zhang K., Lu J., Mori T., Smith-Powell L., Synold T.W., Chen S., Wen W. Baicalin increases VEGF expression and angiogenesis by activating the ERR{alpha}/PGC-1{alpha} pathway. Cardiovasc. Res. 2011, 89:426-435.
182. Zhao D., Desai S., Zeng H. VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: role in VEGF-induced angiogenesis. Int. J. Cancer 2011, 128:2602-2612.
183. Zhao Y., Howatt D.A., Gizard F., Nomiyama T., Findeisen H.M., Heywood E.B., Jones K.L., Conneely O.M., Daugherty A., Bruemmer D. Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte adhesion and atherosclerosis. Circ. Res. 2010, 107:501-511.
184. Zheng B., Han M., Shu Y.N., Li Y.J., Miao S.B., Zhang X.H., Shi H.J., Zhang T., Wen J.K. HDAC2 phosphorylation-dependent Klf5 deacetylation and RARalpha acetylation induced by RAR agonist switch the transcription regulatory programs of p21 in VSMCs. Cell Res. 2011, 21:1487-1508.
185. Zhou C., King N., Chen K.Y., Breslow J.L. Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J. Lipid Res. 2009, 50:2004-2013.
186. Zhou J., Febbraio M., Wada T., Zhai Y., Kuruba R., He J., Lee J.H., Khadem S., Ren S., Li S., Silverstein R.L., Xie W. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR and PPARgamma in promoting steatosis. Gastroenterology 2008, 134:556-567.
187. Zhu Y., Bian Z., Lu P., Karas R.H., Bao L., Cox D., Hodgin J., Shaul P.W., Thoren P., Smithies O., Gustafsson J.A., Mendelsohn M.E. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science 2002, 295:505-508.